Innovative evolution of cancer gene and cellular therapies

P. Lam, G. Khan, R. Stripecke, K. M. Hui, Noriyuki Kasahara, K. W. Peng, B. A. Guinn

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We provide an overview of the latest developments in cancer gene therapy - from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the 'Valley of Death'. treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen's acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalCancer Gene Therapy
Volume20
Issue number3
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Neoplasm Genes
Genetic Therapy
Biotechnology
Clinical Trials
Pharmaceutical Preparations
Neoplasms

Keywords

  • cancer research
  • immunotherapy
  • stem cells

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Lam, P., Khan, G., Stripecke, R., Hui, K. M., Kasahara, N., Peng, K. W., & Guinn, B. A. (2013). Innovative evolution of cancer gene and cellular therapies. Cancer Gene Therapy, 20(3), 141-149. https://doi.org/10.1038/cgt.2012.93

Innovative evolution of cancer gene and cellular therapies. / Lam, P.; Khan, G.; Stripecke, R.; Hui, K. M.; Kasahara, Noriyuki; Peng, K. W.; Guinn, B. A.

In: Cancer Gene Therapy, Vol. 20, No. 3, 03.2013, p. 141-149.

Research output: Contribution to journalArticle

Lam, P, Khan, G, Stripecke, R, Hui, KM, Kasahara, N, Peng, KW & Guinn, BA 2013, 'Innovative evolution of cancer gene and cellular therapies', Cancer Gene Therapy, vol. 20, no. 3, pp. 141-149. https://doi.org/10.1038/cgt.2012.93
Lam, P. ; Khan, G. ; Stripecke, R. ; Hui, K. M. ; Kasahara, Noriyuki ; Peng, K. W. ; Guinn, B. A. / Innovative evolution of cancer gene and cellular therapies. In: Cancer Gene Therapy. 2013 ; Vol. 20, No. 3. pp. 141-149.
@article{17bdb3975df941c4b129984fb23964f2,
title = "Innovative evolution of cancer gene and cellular therapies",
abstract = "We provide an overview of the latest developments in cancer gene therapy - from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the 'Valley of Death'. treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen's acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.",
keywords = "cancer research, immunotherapy, stem cells",
author = "P. Lam and G. Khan and R. Stripecke and Hui, {K. M.} and Noriyuki Kasahara and Peng, {K. W.} and Guinn, {B. A.}",
year = "2013",
month = "3",
doi = "10.1038/cgt.2012.93",
language = "English (US)",
volume = "20",
pages = "141--149",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Innovative evolution of cancer gene and cellular therapies

AU - Lam, P.

AU - Khan, G.

AU - Stripecke, R.

AU - Hui, K. M.

AU - Kasahara, Noriyuki

AU - Peng, K. W.

AU - Guinn, B. A.

PY - 2013/3

Y1 - 2013/3

N2 - We provide an overview of the latest developments in cancer gene therapy - from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the 'Valley of Death'. treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen's acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.

AB - We provide an overview of the latest developments in cancer gene therapy - from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the 'Valley of Death'. treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen's acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.

KW - cancer research

KW - immunotherapy

KW - stem cells

UR - http://www.scopus.com/inward/record.url?scp=84875211121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875211121&partnerID=8YFLogxK

U2 - 10.1038/cgt.2012.93

DO - 10.1038/cgt.2012.93

M3 - Article

C2 - 23370333

AN - SCOPUS:84875211121

VL - 20

SP - 141

EP - 149

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 3

ER -